Nutra Pharma Corporation (OTCBB: NPHC)
www.NutraPharma.com
Nutra Pharma Presentation September 2009
Company Profile
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.
The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.
Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities.
The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida.
Nutra Pharma Announces Launch of Cobroxin, an Over-The-Counter (OTC) Treatment for Stage 2 (Moderate to Severe) Chronic Pain
Select Products
Cobroxin
Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.
www.Cobroxin.com
Nyloxin
Nyloxin OTC Oral Spray is an oral formulation of diluted cobra venom prepared according to the requirements of the Homeopathic Pharmacopoeia of the United States (HPUS) and its supporting texts.
www.Nyloxin.com
RPI-78M
RPI-78M is being developed for the treatment of Multiple Sclerosis (MS). Other neurological disorders that may be served by
RPI-78M include Myasthenia Gravis (MG), Muscular Dystrophy (MD) and Amyotrophic Lateral Sclerosis (ALS).
RPI-MN
RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and AIDS. It is being developed first for the treatment of HIV.
Executive Management
Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation
Paul F. Reid, Ph.D.
Chief Executive Officer
ReceptoPharm
Neil Roth
President
Designer Diagnostics
Contact Details
Nutra Pharma Corporation
1537 NW 65th Avenue
Plantation, FL 33313
USA
|
